Genmab A/S Files Routine 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Apr 2, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, routine-report
TL;DR
Genmab filed a 6-K, standard procedure, no major news.
AI Summary
Genmab A/S filed a Form 6-K on April 2, 2024, to report information for the month of April 2024. This report is incorporated by reference into Genmab A/S's existing S-8 registration statements (File Nos. 333-232693, 333-253519, 333-262970, and 333-277273). The filing does not contain specific financial figures or operational updates beyond its routine reporting nature.
Why It Matters
This filing serves as a routine update for investors and regulators, ensuring transparency regarding Genmab A/S's ongoing reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material information or significant financial disclosures.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-004575 (filing_id) — Accession Number
- 333-232693 (registration_statement_id) — S-8 Registration Statement File Number
- 333-253519 (registration_statement_id) — S-8 Registration Statement File Number
- 333-262970 (registration_statement_id) — S-8 Registration Statement File Number
- 333-277273 (registration_statement_id) — S-8 Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The Form 6-K is a report of a foreign private issuer filed for the month of April 2024, intended to provide information to the SEC and investors.
Which registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 2, 2024.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Does this filing indicate any new financial results or material events for Genmab A/S?
No, this filing is a routine report and does not appear to disclose new financial results or material events beyond its standard reporting requirements.
Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-04-02 09:10:39
Filing Documents
- tmb-20240402x6k.htm (6-K) — 19KB
- tmb-20240402xex99d1.htm (EX-99.1) — 66KB
- tmb-20240402xex99d1a.htm (EX-99.1(A)) — 2787KB
- tmb-20240402xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240402xex99d1a001.jpg (GRAPHIC) — 5KB
- 0001558370-24-004575.txt ( ) — 2886KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: April 2, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated April 2, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix: Share Buy-Back Program Transactions March 25 to 29, 2024